Theravance Biopharma, Inc. (TBPH) Institutional Ownership

Ownership Summary

Theravance Biopharma, Inc. (NASDAQ:TBPH) appears in 166 institutional 13F filings for the quarter ending December 2025.

• These investors collectively held 95.5% of Theravance Biopharma's outstanding shares in December 2025, up from 94.8% in September 2025.
• They increased total shares held in Theravance Biopharma by 2.17% from the prior quarter, while the number of investors in TBPH increased 30.71% year over year.
• Among the 166 funds, 95 bought more Theravance Biopharma shares, 47 sold down, and 24 held their ground.
• In total, institutional investors held 49.56Mn shares in Theravance Biopharma as of December 2025, up by 1.05Mn shares quarter on quarter, and up 4.13Mn shares year over year.
• As of December 31, 2025, the biggest holder of Theravance Biopharma is Madison Avenue Partners, LP at 9.51Mn shares, representing 18.32% of shares outstanding.
• Top purchasers of TBPH stock for the quarter ending December 2025 included VANGUARD CAPITAL MANAGEMENT LLC (1.78Mn), TWO SIGMA INVESTMENTS, LP (721.16K), Newtyn Management, LLC (541.63K), VANGUARD PORTFOLIO MANAGEMENT LLC (400.76K), Janus Henderson Group Plc (357.46K).
• The largest sales of TBPH for the quarter ending December 2025 came from ARROWSTREET CAPITAL, LIMITED PARTNERSHIP (635.71K), D. E. Shaw & Co., Inc. (305.9K), Morgan Stanley (292.85K), Jpmorgan Chase & Co (289.14K), MARSHALL WACE, LLP (259.73K).
• Theravance Biopharma's 10 largest shareholders as of December 2025 include Madison Avenue Partners, LP (9.51Mn), Weiss Asset Management LP (7.46Mn), Newtyn Management, LLC (4.84Mn), BlackRock, Inc. (4.3Mn), Irenic Capital Management LP (2.76Mn), VANGUARD CAPITAL MANAGEMENT LLC (1.78Mn), State Street Corp (1.3Mn), ACADIAN ASSET MANAGEMENT LLC (1.28Mn), TWO SIGMA INVESTMENTS, LP (1.26Mn), GEODE CAPITAL MANAGEMENT, LLC (1.14Mn) per Business Quant data.